癌症的“被遗忘权”：8个欧盟国家医疗法律参数的比较

Q3 Medicine

Ethics, Medicine and Public Health Pub Date : 2025-01-01 DOI:10.1016/j.jemep.2025.101150

M. Marrone, M. Rainò, F. Pititto, G. Pulin, E. Paladini, B.P. De Luca, C. Angeletti, A. Dell’Erba, R. Bellacicco

{"title":"癌症的“被遗忘权”：8个欧盟国家医疗法律参数的比较","authors":"M. Marrone, M. Rainò, F. Pititto, G. Pulin, E. Paladini, B.P. De Luca, C. Angeletti, A. Dell’Erba, R. Bellacicco","doi":"10.1016/j.jemep.2025.101150","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cancer’s ‘Right to be forgotten’ is a form of protection that several EU countries are beginning to recognise for citizens, aimed at ensuring the correspondence between the clinical recovery of a cancer patient and equal access to financial services, banking, insurance and child adoption procedures. The first EU country to enact an oncology oblivion law was France in 2016. Subsequently, other EU countries enacted specific laws on oncological forgetting. The EU Parliament intervened on the topic in 2022, which passed Resolution No. 2020/2267 (INI) calling on all member countries to amend national legislation by 2025. With this resolution, the EU Parliament asked member states to guarantee the right to be forgotten to all patients after 10 years after the end of cancer treatment and after 5 years for patients under 18 years of age.</div></div><div><h3>Methodology</h3><div>The aim of this paper is to compare the regulations of 8 EU countries (France, Belgium, Luxembourg, Netherlands, Spain, Portugal, Romania and Italy) and the different medico-legal parameters adopted.</div></div><div><h3>Results/Discussion</h3><div>The study demonstrated a heterogeneity of tumour-specific medico-legal parameters in the analysed countries. The reason for this heterogeneity could be influenced by a different prevalence and incidence of the tumour forms in the tables and by a different health, insurance and banking organisation, as well as by a different sensitivity of the political decision-maker to the demands of citizens and stakeholders.</div></div><div><h3>Conclusion</h3><div>A common European reflection between scientific professionals, stakeholders, legislators and patients' representatives is desirable and could lead to a homogeneity of tumour-specific cut-offs between EU countries. Furthermore, the table should be updated periodically by a commission of specialists responsible for comparing states; other possible tumour forms should be considered (e.g. adrenal gland cancer, gallbladder cancer, etc.) and it should be possible to integrate the tabular data with a possible case-specific evaluation upon request of the patient.</div></div>","PeriodicalId":37707,"journal":{"name":"Ethics, Medicine and Public Health","volume":"33 ","pages":"Article 101150"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cancer’s “Right to be forgotten”: Comparison of medico-legal parameters in 8 EU countries\",\"authors\":\"M. Marrone, M. Rainò, F. Pititto, G. Pulin, E. Paladini, B.P. De Luca, C. Angeletti, A. Dell’Erba, R. Bellacicco\",\"doi\":\"10.1016/j.jemep.2025.101150\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Cancer’s ‘Right to be forgotten’ is a form of protection that several EU countries are beginning to recognise for citizens, aimed at ensuring the correspondence between the clinical recovery of a cancer patient and equal access to financial services, banking, insurance and child adoption procedures. The first EU country to enact an oncology oblivion law was France in 2016. Subsequently, other EU countries enacted specific laws on oncological forgetting. The EU Parliament intervened on the topic in 2022, which passed Resolution No. 2020/2267 (INI) calling on all member countries to amend national legislation by 2025. With this resolution, the EU Parliament asked member states to guarantee the right to be forgotten to all patients after 10 years after the end of cancer treatment and after 5 years for patients under 18 years of age.</div></div><div><h3>Methodology</h3><div>The aim of this paper is to compare the regulations of 8 EU countries (France, Belgium, Luxembourg, Netherlands, Spain, Portugal, Romania and Italy) and the different medico-legal parameters adopted.</div></div><div><h3>Results/Discussion</h3><div>The study demonstrated a heterogeneity of tumour-specific medico-legal parameters in the analysed countries. The reason for this heterogeneity could be influenced by a different prevalence and incidence of the tumour forms in the tables and by a different health, insurance and banking organisation, as well as by a different sensitivity of the political decision-maker to the demands of citizens and stakeholders.</div></div><div><h3>Conclusion</h3><div>A common European reflection between scientific professionals, stakeholders, legislators and patients' representatives is desirable and could lead to a homogeneity of tumour-specific cut-offs between EU countries. Furthermore, the table should be updated periodically by a commission of specialists responsible for comparing states; other possible tumour forms should be considered (e.g. adrenal gland cancer, gallbladder cancer, etc.) and it should be possible to integrate the tabular data with a possible case-specific evaluation upon request of the patient.</div></div>\",\"PeriodicalId\":37707,\"journal\":{\"name\":\"Ethics, Medicine and Public Health\",\"volume\":\"33 \",\"pages\":\"Article 101150\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ethics, Medicine and Public Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2352552525001094\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ethics, Medicine and Public Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352552525001094","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

癌症的“被遗忘权”是一些欧盟国家开始承认的一种公民保护形式，旨在确保癌症患者的临床康复与获得金融服务、银行、保险和儿童收养程序的平等机会之间的对应。2016年，法国成为第一个颁布肿瘤学遗忘法的欧盟国家。随后，其他欧盟国家制定了针对肿瘤遗忘的具体法律。欧盟议会于2022年介入该主题，通过了第2020/2267号决议（INI），呼吁所有成员国在2025年之前修改国家立法。通过这项决议，欧盟议会要求成员国保障所有癌症治疗结束后10年和18岁以下患者5年后被遗忘的权利。方法本文的目的是比较8个欧盟国家（法国、比利时、卢森堡、荷兰、西班牙、葡萄牙、罗马尼亚和意大利）的法规和采用的不同医疗法律参数。结果/讨论该研究表明，在所分析的国家中，肿瘤特异性医学-法律参数存在异质性。造成这种异质性的原因可能受到下列因素的影响：表中肿瘤形式的流行率和发病率不同；健康、保险和银行组织不同；政治决策者对公民和利益攸关方要求的敏感度不同。科学专业人员、利益相关者、立法者和患者代表之间的共同欧洲反思是可取的，并可能导致欧盟国家之间肿瘤特异性切断的同质性。此外，该表应由负责比较各国的专家委员会定期更新；应考虑其他可能的肿瘤形式（如肾上腺癌、胆囊癌等），并应患者要求将表格数据与可能的病例特异性评估结合起来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cancer’s “Right to be forgotten”: Comparison of medico-legal parameters in 8 EU countries

Background

Cancer’s ‘Right to be forgotten’ is a form of protection that several EU countries are beginning to recognise for citizens, aimed at ensuring the correspondence between the clinical recovery of a cancer patient and equal access to financial services, banking, insurance and child adoption procedures. The first EU country to enact an oncology oblivion law was France in 2016. Subsequently, other EU countries enacted specific laws on oncological forgetting. The EU Parliament intervened on the topic in 2022, which passed Resolution No. 2020/2267 (INI) calling on all member countries to amend national legislation by 2025. With this resolution, the EU Parliament asked member states to guarantee the right to be forgotten to all patients after 10 years after the end of cancer treatment and after 5 years for patients under 18 years of age.

Methodology

The aim of this paper is to compare the regulations of 8 EU countries (France, Belgium, Luxembourg, Netherlands, Spain, Portugal, Romania and Italy) and the different medico-legal parameters adopted.

Results/Discussion

The study demonstrated a heterogeneity of tumour-specific medico-legal parameters in the analysed countries. The reason for this heterogeneity could be influenced by a different prevalence and incidence of the tumour forms in the tables and by a different health, insurance and banking organisation, as well as by a different sensitivity of the political decision-maker to the demands of citizens and stakeholders.

Conclusion

A common European reflection between scientific professionals, stakeholders, legislators and patients' representatives is desirable and could lead to a homogeneity of tumour-specific cut-offs between EU countries. Furthermore, the table should be updated periodically by a commission of specialists responsible for comparing states; other possible tumour forms should be considered (e.g. adrenal gland cancer, gallbladder cancer, etc.) and it should be possible to integrate the tabular data with a possible case-specific evaluation upon request of the patient.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ethics, Medicine and Public Health Medicine-Health Policy

CiteScore

2.20

自引率

0.00%

发文量

107

审稿时长

42 days

期刊介绍： This review aims to compare approaches to medical ethics and bioethics in two forms, Anglo-Saxon (Ethics, Medicine and Public Health) and French (Ethique, Médecine et Politiques Publiques). Thus, in their native languages, the authors will present research on the legitimacy of the practice and appreciation of the consequences of acts towards patients as compared to the limits acceptable by the community, as illustrated by the democratic debate.